Mammoth Biosciences
Aashish Lamichhane is a skilled scientist with extensive experience in downstream process development, particularly in gene therapy and AAV vectors. Currently serving as a Principal Scientist I at Mammoth Biosciences since August 2023, Aashish previously held the position of Senior Scientist I at Encoded Therapeutics Inc., from November 2018 to July 2023, where responsibilities included scientific leadership across various roles. Earlier experience includes positions at BioMarin Pharmaceutical Inc., focusing on purification process development for gene therapy candidates, and teaching roles at the University of California San Diego, where Aashish also conducted research on Fibrolamellar Hepatocellular Carcinoma. Aashish's academic background includes a Master of Science in Chemistry and Biochemistry and a Bachelor of Science in Biological Sciences, complemented by a minor in Chemistry.
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.